A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
| 対象疾患 | Multiple Myeloma |
|---|---|
| 相 | 第3相 |
| スポンサー | Janssen Research & Development, LLC |
| ステータス | 実施中（募集終了） |
| 参加者数 | 419 名 |
| 介入（薬剤） | Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab |
| 開始日 | 2020年6月12日 |
| 完了日 | 2024年5月1日 |
| 結果公開日 | 2025年5月20日 |
概要
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
Progression Free Survival (PFS)
| Arm A: Standard Therapy: PVd or DPd | 11.79 months |
|---|---|
| Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | NA months |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) a — University of Alabama at Birmingham
- Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myel — M.D. Anderson Cancer Center